Author

Doris Auth

Observed names: D A Auth, Doris A. Auth

Institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research

Observed institutions: National Institutes of Health, United States Food and Drug Administration, Center for Drug Evaluation and Research, American Nurses Credentialing Center, National Institutes of Health Clinical Center

ORCID: 0009-0002-4693-4303

Observed ORCID: 0009-0002-4693-4303

OpenAlex ID: A5076166988

FDA Approval Summary: Tucatinib with Trastuzumab for Advanced Unresectable or Metastatic, Chemotherapy Refractory, HER2 -Positive RAS Wild-Type Colorectal Cancer

2023 · Sandra J. Casak, M. Naomi Horiba, et al. · Clinical Cancer Research · 37

FDA Approval Summary: Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

2024 · Michael J. Fusco, Sandra J. Casak, et al. · Clinical Cancer Research · 30

FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer

2024 · Sandra J. Casak, Vaibhav Kumar, et al. · Clinical Cancer Research · 29

Risk Management for the 21st Century: Current Status and Future Needs

2021 · Rania Mouchantaf, Doris Auth, et al. · Drug Safety · 26

FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements

2023 · Shruti U. Gandhy, Sandra J. Casak, et al. · Clinical Cancer Research · 25

Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing

2019 · William Fleischman, Doris Auth, et al. · JAMA Network Open · 14

Acute Toxic Delirium

1995 · P J Kuzma, M D Kline, et al. · Anesthesiology · 14

A Collaboration Between Government and the Continuing Education Community Tackles the Opioid Crisis: Lessons Learned and Future Opportunities

2019 · Norman Kahn, Kathy Chappell, et al. · Journal of Continuing Education in the Health Professions · 11

Quality of Pharmacotherapy Consultations Provided by Drug Information Centers in the United States

2000 · Karim Anton Calis, Dallas W. Anderson, et al. · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 8

FDA Approval Summary: Pembrolizumab for the Treatment of HER2-Positive Gastric Cancer

2026 · Sandra J. Casak, Yiming Zhang, et al. · Clinical Cancer Research · 2

FDA Approval Summary: Retifanlimab for the Treatment of Adult Patients with Metastatic or Inoperable Locally Recurrent Squamous Cell Carcinoma of the Anal Canal

2026 · Shruti U. Gandhy, Sandra J. Casak, et al. · Clinical Cancer Research

Assessing the Opioid Analgesic Risk Evaluation and Mitigation Strategy Program

2020 · Doris Auth, Judy Staffa, et al. · JAMA Internal Medicine

Works count: 12

Citation count: 196

H-index: 8

I10-index: 8